129 related articles for article (PubMed ID: 23870855)
21. Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.
Börschel N; Schwöppe C; Zerbst C; Angenendt L; Kessler T; Klapper W; Giovannoni L; Elia G; Neri D; Berdel WE; Mesters RM; Schliemann C
Leuk Res; 2015 Jul; 39(7):739-48. PubMed ID: 25934049
[TBL] [Abstract][Full Text] [Related]
22. Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma.
Dietrich S; Weidle J; Rieger M; Meissner J; Radujkovic A; Ho AD; Dreger P; Witzens-Harig M
Leukemia; 2014 Mar; 28(3):708-9. PubMed ID: 24217198
[No Abstract] [Full Text] [Related]
23. Rituximab-induced Acute Thrombocytopenia in High Tumor Burden Follicular Lymphoma.
Ureshino H; Nishioka A; Kojima K; Suzuki M; Kizuka H; Sano H; Shindo T; Kubota Y; Ando T; Kimura S
Intern Med; 2016; 55(15):2061-4. PubMed ID: 27477415
[TBL] [Abstract][Full Text] [Related]
24. Rituximab induced myocardial infarction: A fatal drug reaction.
Arunprasath P; Gobu P; Dubashi B; Satheesh S; Balachander J
J Cancer Res Ther; 2011; 7(3):346-8. PubMed ID: 22044821
[No Abstract] [Full Text] [Related]
25. Hyperinfection by Strongyloides stercoralis probably associated with Rituximab in a patient with mantle cell lymphoma and hyper eosinophilia.
Incani RN; Hernández M; González ME
Rev Inst Med Trop Sao Paulo; 2010; 52(4):221-4. PubMed ID: 21748232
[TBL] [Abstract][Full Text] [Related]
26. Four cases of rituximab-associated melanoma.
Velter C; Pagès C; Schneider P; Osio A; Brice P; Lebbé C
Melanoma Res; 2014 Aug; 24(4):401-3. PubMed ID: 24743053
[TBL] [Abstract][Full Text] [Related]
27. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
[No Abstract] [Full Text] [Related]
28. Late-onset neutropenia following viral bone marrow depression after rituximab therapy.
Christopeit M; Haak U; Behre G
Ann Hematol; 2008 Sep; 87(9):761-2. PubMed ID: 18350295
[No Abstract] [Full Text] [Related]
29. Multiple lymphomatous polyposis as a sole presentation of mantle cell lymphoma.
Mar N; Khaled S; Kencana F; Gergis U; Khattak F; Brodsky N; Gotlieb V
J Clin Gastroenterol; 2006 Aug; 40(7):653-4. PubMed ID: 16917415
[No Abstract] [Full Text] [Related]
30. Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphoma.
Debatin L; Schmitt-Graeff A; Veelken H
Onkologie; 2011; 34(6):322-4. PubMed ID: 21625186
[No Abstract] [Full Text] [Related]
31. Prognostic value of platelet count in diffuse large B-cell lymphoma.
Chen LP; Lin SJ; Yu MS
Clin Lymphoma Myeloma Leuk; 2012 Feb; 12(1):32-7. PubMed ID: 22138101
[TBL] [Abstract][Full Text] [Related]
32. Treatment of synchronous mantle cell lymphoma and small lymphocytic lymphoma with bendamustine and rituximab.
Kourelis TV; Kahl BS; Benn P; Delach JA; Bilgrami SF
Acta Haematol; 2011; 126(1):40-3. PubMed ID: 21430370
[TBL] [Abstract][Full Text] [Related]
33. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
34. Thrombocytopenia with rituximab treatment--splenomegaly as the risk factor.
Adiyodi J; Thachil J; Hawkins S; Hincks I; Woodcock BE; Salim R
Ann Hematol; 2010 Jan; 89(1):95-6. PubMed ID: 19506870
[No Abstract] [Full Text] [Related]
35. [Subcutaneous Rituximab is effective and safe].
Häckel A
Med Monatsschr Pharm; 2014 Jan; 37(1):39-40. PubMed ID: 24490439
[No Abstract] [Full Text] [Related]
36. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma.
Cho CH; Hwang WL; Cheng SB; Lee TY; Teng CL
Ann Hematol; 2011 Jan; 90(1):111-2. PubMed ID: 20407894
[No Abstract] [Full Text] [Related]
38. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
39. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
40. [Idiopathic thrombocytopenic purpura associated with mantle cell lymphoma showing an increase in the platelet count receiving anti-CD20 antibody rituximab].
Kawachi Y; Ide M; Uchida T; Setsu K
Rinsho Ketsueki; 2003 Jan; 44(1):31-3. PubMed ID: 12649836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
